Nippon Express USA Acquires GDP Certification for CFS in Los Angeles and New York
TOKYO, March 8, 2022 /PRNewswire/ -- Nippon Express USA, Inc. (hereinafter "NX USA"), a group company of Nippon Express Holdings, Inc., has obtained Good Distribution Practice (GDP) certification for forwarding operations, inclusive of temporary storage, at temperature-controlled facilities in its CFS near Los Angeles International Airport (effective November 23, 2021) and its CFS near John F. Kennedy International...
Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC
HONG KONG, March 8, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the development of innovative antibody drugs, today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the IND application for the initiation of the open-label, multicenter phase II trial in China using Cadonilimab (PD-1/CTLA-4...
World Alliance for Mercury-Free Dentistry announces: Nonprofit groups from 48 countries call for VIC-based Southern Dental Industries to exit selling mercury fillings to ‘lower soci-economic markets’
WASHINGTON, March 8, 2022 /PRNewswire/ -- Alarmed that Victoria-based Southern Dental Industries intends to keep selling mercury fillings (dental amalgam) to 'lower soci-economic markets' rather than its supply of non-polluting alternatives, 64 civil society organisations from 48 nations call on its CEO, Samantha Cheetham, to halt the practice. https://mercuryfreedentistry.files.wordpress.com/2022/03/intl-ngos-to-southern-dental-22.2.22_.pdf The subject of an international treaty which mandates scaling down...
WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies
PHILADELPHIA, March 8, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manufacture of adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. Developed by OXGENE in the United Kingdom, a WuXi Advanced Therapies...
Bridge Biotherapeutics Enters into an Option-to-License Agreement with CellionBioMed to Develop BBT-301 for the Treatment of Multiple Fibrotic Diseases
The company reinforces its strategic focus on fibrotic diseases including idiopathic pulmonary fibrosis (IPF) Through the option-to-license agreement, Bridge will develop a novel anti-fibrotic ion channel modulator, which is a preclinical candidate SEONGNAM, South Korea, March 8, 2022 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for fibrosis,...
Suvoda Unveils New Brand to Reflect Expanded Focus in Complex Clinical Trial Management
Alongside brand refresh, leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey. PHILADELPHIA, March 8, 2022 /PRNewswire/ -- Suvoda LLC today launched a refreshed brand, to better reflect its leadership position as a global clinical trial technology company that specializes in highly complex studies,...
Singleron Acquires Proteona
NANJING/SUZHOU, China and COLOGNE, Germany and SINGAPORE, March 7, 2022 /PRNewswire/ -- Singleron Biotechnologies, a leading Chinese genomics company that develops groundbreaking single-cell multi-omics platform technologies and promotes their clinical translations, today announced the acquisition of Proteona Pte. Ltd., a Singapore-based precision medicine company offering single-cell biomarker discovery services to translational and clinical researchers across the globe. By acquiring...
Happiness Development to Acquire Hekangyuan, One of the Largest Healthcare Product Distributors in Fuzhou Area in China
NANPING, China, March 7, 2022 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"), (NASDAQ: HAPP) an emerging and diversified company engaging in the business of production of nutraceutical and dietary supplements, providing e-commerce sales and e-commerce marketing solutions, and the sales of automobile today announced that it has signed an equity transfer agreement (the "Agreement") to acquire 100% of the equity...
Alterity Therapeutics to Present at the 34th Annual Roth Conference
MELBOURNE, Australia and SAN FRANCISCO, March 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present a company update and participate in investor meetings at the 34th Annual Roth Conference. The conference is taking place Monday,...
Turn Bio adds veteran executives with decades of international business development, intellectual property expertise
Hires will help to expand Turn's commercial reach, protect its unique ERA Platform technology MOUNTAIN VIEW, Calif., March 7, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure now-untreatable, chronic, age-related conditions, today announced the addition of global expertise in partnership development and intellectual property protection. Turn has hired two executives with...
